Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)

Regional University Hospital Center (CHRU)

Status: Active, not recruiting

Conditions: Myeloproliferative Neoplasm

Study type: Observational

Funder types: Other

Identifiers

NCT06553638

29BRC24.0132 - PRODIGE

Details and patient eligibility

About

50 patients with a diagnosis of MPN will have an assessment of b2microglobuline at diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• MPN patient diagnosed at one of the participating centers
• over 18 yo

Exclusion criteria

• Not able to consent